Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Min Wang; Yanxing Chen; Lin Tian; Chenyi Wu; Jiaying Chen; Jiajia Hu; Runjie Huang; Yingnan Wang; Jinling Zhang; Xiaojun Ouyang; Liqin Wang; Ying Jin; Qi Zhao; Feng Wang; Rui‐Hua Xu

doi:10.1158/2159-8290.30050814

September 4, 2025Open Access

Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combined HDAC inhibitors and immunotherapy enhance antitumor efficacy in solid tumors, indicating a promising therapeutic approach.
The study utilizes flow cytometry to assess the gating strategy of main cell types and T cells, crucial for understanding treatment impact.
Assessment through flow cytometry highlights the importance of vascular normalization in enhancing overall antitumor effects.
These findings point to the potential of using vascular normalization strategies in concurrent treatment regimens for solid tumors.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Findings demonstrate increased antitumor efficacy in solid tumors with combined HDAC inhibitors and immunotherapy, suggesting vascular normalization plays a critical role.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c18c089b7b07f3a061486e https://doi.org/10.1158/2159-8290.30050814

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S10 from Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading